ARROW update demonstrates first-line pralsetinib benefit for advanced RET fusion-positive NSCLC
Updated findings from the ARROW trial show that pralsetinib has “robust efficacy” for the first-line treatment of locally advanced or metastatic, RET fusion-positive, non-small-cell lung cancer, the investigators say.
Large proportion of global cancer deaths, DALYs attributable to modifiable risk factors
Modifiable risk factors accounted for almost half of the global cancer mortality and disability-adjusted life–years in 2019, shows an analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study.
Trastuzumab deruxtecan-related ILD/pneumonitis characterized
A pooled analysis of nine early-phase trials of trastuzumab deruxtecan monotherapy has identified an incidence of drug-related interstitial lung disease/pneumonitis of 15.4%.
NADIM II: Adding nivolumab to neoadjuvant chemo improves stage III NSCLC survival
The addition of nivolumab to neoadjuvant chemotherapy significantly improves the survival of individuals with resectable stage IIIA–B non-small-cell lung cancer, suggest data from NADIM II.
Adolescent, young adult patients might benefit from intensive rhabdomyosarcoma treatment
Adolescent and young adults with rhabdomyosarcoma have more aggressive disease than their paediatric counterparts and might benefit from intensive treatment strategies, suggests an analysis of two European paediatric Soft tissue sarcoma Study Group trials.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
KEYNOTE-355 shows OS benefit with pembrolizumab–chemo in advanced TNBC
Adding pembrolizumab to chemotherapy significantly improves the overall survival of people with advanced triple-negative breast cancer and a tumoral PD-L1 combined positive score of at least 10, demonstrate phase 3 trial data.
ICIs associated with increased MACE risk
People with cancer receiving immune checkpoint inhibitors have a significantly higher risk for major adverse cardiovascular events than their unexposed counterparts or the general population, indicate real-world findings.
Cancer screening declined globally during COVID-19 pandemic
A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.
Real-world data magnify abemaciclib–thrombosis link in breast cancer
The incidence of thrombosis among people receiving the CDK4/6 inhibitor abemaciclib for metastatic breast cancer is approximately threefold higher in a real-world setting than that observed in clinical trials, US study data show.
No increased hemorrhage risk with concurrent tamoxifen, oral anticoagulants
Using tamoxifen alongside a direct oral anticoagulant does not increase major hemorrhage risk versus concurrent aromatase inhibitor use in breast cancer.
